BI1206-03 (Keynote-A04)
A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors.
Links
An der Studie beteiligte Zentren
Zentrum
Hauttumorzentrum der Universitäts-Hautklinik und des NCT Heidelberg Im Neuenheimer Feld 440/460 69120 Heidelberg Deutschland
Kontakt
Frau Dr. Ines Bertlich Hauttumorzentrum@med.uni-heidelberg.de